Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Urticaria; Pruritic skin disorders As alimemazine tartrate: 10 mg bid or tid. Refractory cases: Up to 100 mg/day.
May be taken with or without food.
Epilepsy, parkinsonism, hypothyroidism, phaechromocytoma, myasthenia gravis, prostatic hypertrophy, history of narrow angle glaucoma. Renal and hepatic impairment. Childn <2 yr. Lactation.
Special Precautions
Patient w/ volume depletion, CV disease, chronic constipation, pyloroduodenal obstruction, urinary retention, history of seizure. Childn and elderly. Pregnancy. Patient Counselling Avoid alcohol intake and exposure to sunlight. This drug may cause drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor vital signs and mental status.
Adverse Reactions
Nasal stuffiness, dry mouth, insomnia, agitation, convulsion; jaundice; hypotension, pallor; AV block, ventricular tachycardia and fibrillation; ECG changes; mild leucopenia, unexplained fever/infection; acute dystonia/dyskinesia, akathisia, parkinsonism, tremor, rigidity, akinesia, tardive dyskinesia; skin rashes, photosensitivity, ocular changes, metallic greyish-mauve colouration of skin; hyperprolactinaemia (i.e. galactorrhoea, gynaecomastia, amenorrhoea, impotence); neuroleptic malignant syndrome (i.e. hyperthermia, autonomic dysfunction, altered consciousness); paradoxical excitement. Rarely, agranulocytosis, contact skin sensitisation.
Drug Interactions
Intensified sedative effect w/ anxiolytics, hypnotics, opiates, barbiturates, and other sedatives. Interfered absorption w/ antacids, antiparkinson agents, and lithium. May exaggerate the hypotensive effects of antihypertensive drugs esp α-adrenoreceptor blockers. May increase side effects of antimuscarinics. May oppose actions of amphetamine, levodopa, clonidine, guanethidine, and epinephrine. May reduce the response to hypoglycaemic agents.
ATC Classification
R06AD01 - alimemazine ; Belongs to the class of phenothiazine derivatives used as systemic antihistamines.
Disclaimer: This information is independently developed by CIMS based on alimemazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in